A class action lawsuit against three diabetes drugmakers appears to lack a substantive legal argument, but if it does happen to gain any traction in the courts, the suit could put the whole pharmacy benefit manager (PBM) rebate model under legal scrutiny.
The lawsuit, filed by Hagens Berman Sobol Shapiro, alleges that Sanofi,Eli Lilly & Co. and Novo Nordisk AS...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?